ANZCTR search results

This study will explore the role that supervised exercise training has in helping Stage I or II lung cancer patients to recover. Who is it for? You can join this study if you have previously had a lung resection (lobectomy) for lung cancer (Stage I or II non-small cell). With or without chemotherapy, and live in the metropolitan Perth area. Trial Details Following completion of previous treatment for lung cancer (surgery with or without chemotherapy), you will be randomised either to a group that receives 8 weeks of supervised exercise training, or usual care where you will be followed up by weekly phone calls for general discussion about your recover. Measures will be made before and after this 'intervention' period. Specifically, measures will be made of; (i) lung function, (ii) exercise capacity, (iii) disease-specific health-related quality of life, (iv) feelings of anxiety and depression, (v) peripheral muscle force (i.e. strength) and, (vi) daily physical activity. This trial will be the first randomised controlled trial of supervised out-patient exercise training in this patient population, and look to optimise recovery for patients following lung cancer resection.

For antenatal screening for Group B Streptococcus (GBS), current guidelines from the Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG) recommend both a low vaginal swab (LVS) and an anorectal swab (ARS) to be taken. The addition of an ARS to a LVS is reported to increase the GBS detection rate compared to performing a LVS alone. Despite these recommendations, many clinicians perform a LVS alone for GBS screening, and patient and physician acceptability may be responsible. We aim to assess the pain and acceptability of the LVS and ARS, and the detection rate for GBS from each swab.

The purpose of this study is two compare the benefit of two different treatments for patients with stress urinary incontinence. This is a condition in which women may leak urine with increases in abdominal pressure, such as coughing, sneezing, lifting, walking or running. The first treatment is five individual physiotherapy sessions. The second treatment is 20 sessions on a special magnetic chair. Patients are assessed prior to starting treatment, at three months after competing treatment, and again at six months.

Objective: The current trial examined whether the inclusion of a parental anxiety management (PAM) program in addition to family cognitive-behavioral therapy (CBT) was more efficacious than family CBT only in treating childhood anxiety disorders. Method: Two hundred and nine children (aged 6-13 years) with a principal anxiety disorder were randomly allocated to a 5 session PAM program (n = 109) in addition to family CBT or family CBT only. Results: Overall, results revealed that the addition of PAM did not significantly improve principal anxiety diagnostic outcomes for the child or the parent compared to the CBT only group at post-treatment and 6-month follow-up. Results further suggest that children with non-anxious parents were more likely to be diagnosis-free for any anxiety disorder compared to children with anxious parents at post-treatment and 6-mth follow-up. Conclusions: The present findings indicate that the addition of PAM in its current format did not lead to additional gains in diagnostic status when used as an adjunct to family CBT in the treatment of the child’s anxiety disorder. The addition of PAM did not lead to a sufficient decline in parental anxiety disorders over and above the decline observed across time for children receiving CBT. Parental anxiety status impacted on child diagnostic outcome: Children were less likely to be diagnosis-free following treatment if they had a parent who also had an anxiety disorder.

Sleep is commonly disturbed during pregnancy and following childbirth. Even individuals who have been ‘healthy sleepers’ will notice a change in their sleep patterns during pregnancy. Given the high associations between sleep deprivation and depression amongst insomnia patients and depressed patients, it is important to note that sleep deprivation may be one factor that contributes to a greater propensity for women to become depressed in the post-natal period compared to other periods in their life. Post Natal Depression (PND) is common yet rarely acknowledged until after the full onset of symptoms negatively affecting all family members. The aim of the current study is to educate and prepare first time parents about sleep and sleep management with a new baby. First time mothers attending prenatal classes will be approached during the last trimester of their pregnancy and randomised to either a sleep psychoeducational intervention or treatment as usual. The primary aim of this project is to determine the efficacy of a brief pragmatic sleep intervention in improving sleep management and reducing depressive symptoms or prevalence of PND in first time mothers compared with treatment as usual.

Studies indicate that men who have sex with men (MSM) have a high prevalence of anogenital Human papillomavirus (HPV) infection and increased risk for HPV related anogenital lesions including anogenital warts, anal intraepithelial neoplasia ( the abnormal proliferation of cells) and anal cancer. Currently in Australia, HPV vaccine for men is not covered by programs. This study will explore the prevalence of persistent HPV infection, distinguishing this from transient HPV infection and sexual behaviours associated with varying prevalence of HPV infection. We will survey 200 MSM aged 16-20 who just started their sexual life. We will use a questionnaire to collect information of socio-demographic characteristics, lifetime sexual experience, recent sexual experience, the most recent sexual contact, STIs/HIV history and testing history, HPV knowledge and attitude, smoking/alcohol/drug/circumcision. We will also collect oral, penile and anal samples as well as blood samples to test for HPV DNA, mRNA and antibody. The study will include four visits in the 12-month period. In each visit, participants will be asked to fill a questionnaire and provide oral, penile and anal samples as well as blood samples. Each participant will receive $25 at each visit as compensation for their time. All participants will be offered free HPV vaccine at the end of the study.

The aim of this study is to investigate the use of a therapeutic Smartphone application in the delivery of thearpy homework. It is expected that the electronic delivery of homeowrk tasks will facilitate greater patient adherence with these tasks, when compared to pen and paper delivery.

ATL1103 is being developed as a potential treatment for diseases of excessive growth hormone and insulin-like growth hormone (IGF-I) action. This is the first in man study for ATL1103, and is being conducted as a randomized, placebo-controlled, double-blind trial. Thirty six healthy male subjects will participate in the study. In stage A, subjects will receive one dose of either placebo or ATL1103 (at a dose of 25 mg, 75 mg, 250 mg or 400 mg). In stage B, subjects will receive 6 doses of placebo or ATL1103 (at a dose to be determined after review of the safety data from Stage A). All treatments will be administered by subcutaneous injection. The primary objectives of the study is to evaluate the safety and tolerability of single or multiple injections of ATL1103, and to investigate the pharmacokinetic profiles of ATL1103 after subcutaneous administration. The effect of ATL1103 on serum IGF-I levels will also be monitored.

The purpose of this study is to determine cardiac function in pregnant women at the time of the diagnosis of preeclampsia and before any treatment is commenced. The cardiac function at this time will be compared to healthy gestationally matched pregnant women and also to non-pregnant healthy women.

The aim of this study is to determine whether naloxone, an opioid reversal agent, is as effective for the treatment of acute opioid overdose when administered via the intranasal (IN) route compared with the intramuscular route. The term 'opioid' refers to a class of drugs that includes heroin, and the prescription medications oxycontin and morphine. Injection of naloxone into a muscle is currently the standard method of emergency treatment for an opioid overdose on site at the Sydney Medically Supervised Injecting Centre. However, Naloxone can be administered as an intranasal (IN) spray using a 'mucosal atomisation device’. Evidence suggests that IN naloxone may be an effective and practical alternative. The significant benefits of IN administration include removing the risk of needlestick injury (and thus any blood borne virus transmission risk) to treating personnel. This is particularly relevant to ambulance officers and paramedics, as well as other emergency health care workers, such as in the hospital emergency department setting. Additionally, given the ease of administration and reduced issues regarding disposal of used needles, the availability of IN naloxone may potentially be extended. This may include non health care workers who regularly deal with opioid overdose in community settings, and drug users’ peers, who are likely to be present in the event of an overdose. The Sydney Medically Supervised Injecting Centre (MSIC) provides the ideal setting for this study.